Transdermal Drug Delivery System- Design and Evaluation
Keywords:
Transdermal, Drug Delivery, TDDSAbstract
The human skin is a readily accessible surface for drug delivery. Skin of an average adult body covers a surface of approximately 2 m 2 and receives about one-third of the blood circulating through the body. Over the past three decades, developing controlled drug delivery has become increasingly important in the pharmaceutical industry. The human skin surface is known to contain, on an average, 10-70 hair follicles and 200-250 sweat ducts on every square centimeters of the skin area. It is one of the most readily accessible organs of the human body. The potential of using the intact skin as the port of drug administration to the human body has been recognized for several decades, but skin is a very difficult barrier to the ingress of materials allowing only small quantities of a drug to penetrate over a period of time. During the past decade, the number of drugs formulated in the patches has hardly increased, and there has been little change in the composition of the patch systems. Modifications have been mostly limited to refinements of the materials used. The present article reviews the selection of drug candidates suitable to be formulated as Transdermal system and the methods of evaluation.
References
Jasti BR, Abraham W, Ghosh TK.
Transdermal and Topical drug delivery
systems. In : Ghosh TK, Jasti BR, editors.
Theory and Practice of Contemporary
Pharmaceutics. 1st ed. Florida: CRC Press;
p. 423-53.
Baker H. The skin as barrier. In: Rook A,
Wilkinson DS, Ebling FJG, Champion
RH, Burton JL, eds. Text Book of
Dermatology. Vol. I, 4th ed. Oxford:
Blackwell Scientific Publications,
:355-66.
Barr M. Percutaneous absorption, J Pharm
Sci 1962; (61):395-409.
Chein YW. Advances in transdermal
systemic drug delivery. Drugs of Future
; (13):343-62.
Franz TJ, Tojo K. Shah KR, Kydonieus A.
Transdermal delivery. In: A Kydonieus,
ed. Treatise on Controlled Drug Delivery.
New York: Marcel Dekker, 1992:341-421.
Prochazka AV. New developments in
smoking cessation. Chest. 2000;117 (4
Suppl1):169-175.
Hadgraft J. Modulation of the barrier
function of the skin. Skin Pharmacol Appl
Skin Physiol. 2001;(14)(suppl 1):72-81.
Chein YW. Novel Drug Delivery Systems
Revised and expanded. 2nd ed. New York:
Marcel Dekker Inc; 2005.
Riviere JE, Papich MG. Potential and
problems of developing transdermal
patches for veterinary applications. Adv
Drug Deliv Rev. 2001;(50):175-203.
Chandrashekar NS, Shobha Rani RH.
Physicochemical and pharmacokinetic
parameters in drug selection and loading
for transdermal drug delivery. Indian J
Pharm Sci 2008;(70):94-6
Panchagnula R. Transdermal delivery of
drugs. Indian J Pharmacol 1997;(29): 140-
Sadashivaiah R, Dinesh BM, Patil UA,
Desai BG, Raghu KS. Design and in vitro
evaluation of haloperidol lactate
transdermal patches containing ethyl
cellulose-povidone as film formers. Asian
J Pharm 2008;(2):43-9
Taub MB, Dauskardt RH. Adhesion of
pressure sensitive adhesives with
applications in transdermal drug delivery.
In: Mallapragada S, Korsmeyer R,
Mathiowitz E, et al, eds. Biomaterials for
Drug Delivery and Tissue Engineering.
Warrendale, Pa, [Mater. Res. Soc.
Proc.662,2001].
Arora P, Mukherjee P. Design,
development, physicochemical, and in
vitro and in vivo evaluation of transdermal
patches containing diclofenac
diethylammonium salt. J Pharm Sci
;(91):2076-89.
Tojo K. Design and calibration of in vitro
permeation apparatus. In: Chien YW,
editor. Transdermal controlled systemic
medications. New York: Marcel Dekker;
p. 127-58.
Mukherjee B, Mahapatra S, Gupta R, Patra
B, Tiwari A, Arora P. A comparison
between povidone-ethylcellulose and
povidone-eudragit transdermal
dexamethasone matrix patches based on in
vitro skin permeation. Eur J Pharma
Biopharma 2005;(59):475-83
McCarley KD, Bunge AL. Review of
pharmacokinetic models of dermal
absorption. J Pharmaceut Sci.
;(90):1699-1719.
Ghosal SK, Bhattacharya M, Mandal SC.
Invitro release and permeation kinetics of
pentazocaine from matrix dispersion type
transdermal drug delivery systems. Drug
Dev Ind Pharm 1994;(20):1933-41.
Guyot M, Fawaz F. Design and in vitro
evaluation of adhesive matrix for
transdermal delivery of propranolol. Int J
Pharm. 2000;(204):171-182.
Bronaugh RL. Stewart RF, Congdon ER.
(1982) Methods for in vitro percutaneous
absorption studies II. Animal models for
human skin. Toxicol App Pharmacol
;(62):481-8.
Wester RC, Noonan PK. Relevance of
animal models for percutaneous
absorption. Int J Pharm 1980:(7):99-1 10.
Lin, R-Y., Hsu, C-W. and Chein, YW. A
method to predict the transdermal
permeability of amino acids and dipeptides
through porcine skin. J Cont Rel
;(38):229-34.
Benson HA. Transdermal drug delivery:
Penetration enhancement techniques. Curr
Drug Deliv 2005; (2):23-33.
Baynes RE, Monteiro-Riviere NA, Qiao
GL, Riviere JE. Cutaneous toxicity of the
benzidine dye direct red 28 applied as
mechanistically defined chemical mixtures
(MDCM) in perfused porcine skin.
Toxicol Lett. 1997;(93):159-169.
Riviere JE, Papich MG. Potential and
problems of developing transdermal
patches for veterinary applications. Adv
Drug Deliv Rev. 2001;(50):175-203.
Morganti P, Ruocco E, Wolf R, Ruocco V.
Percutaneous absorption and delivery
systems. Clin Dermatol. 2001;(19):489-
Mehta R. Topical and transdermal drug
delivery: What a pharmacist needs to
know. Available at:
www.inetce.com/articles/pdf/146-000-01-
